SCHEMBL21534086

SCHEMBL21534086

Cn1c(-c2ccccn2)cc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.56
ADRA2A P08913 1/20 0.55
KDM4E B2RXH2 7/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.50
NTRK1 P04629 1/20 0.46
TERT O14746 1/20 0.45
CYP11B2 P19099 1/20 0.45
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
LMNA P02545 2/20 0.43
CCR1 P32246 2/20 0.43
CCR5 P51681 2/20 0.43
CCR8 P51685 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
METAP1 P53582 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22004157 0.83 ACLY (0.49) KMT2AADRA2AKDM4EMAPTMEN1
SCHEMBL23320494 0.83 CA12 (0.45) KMT2AADRA2AKDM4EMAPTALDH1A1
SCHEMBL30943245 0.83 CA12 (0.45) KMT2AADRA2AKDM4EMAPTALDH1A1
SCHEMBL22004356 0.80 KMT2A (0.53) KMT2AADRA2AKDM4EMAPTMEN1
SCHEMBL10103705 0.79 KMT2A (0.76) KMT2AADRA2AKDM4EMAPTMEN1
SCHEMBL12278076 0.79 CA12 (0.39) KMT2AADRA2AKDM4EALDH1A1HPGD
SCHEMBL12278039 0.79 CA12 (0.39) KMT2AADRA2AKDM4EMAPTALDH1A1
SCHEMBL12278294 0.78 CA12 (0.43) KDM4EMAPTALDH1A1HPGDCA12
SCHEMBL29533984 0.78 KMT2A (0.50) KMT2AADRA2AKDM4EMAPTMEN1
SCHEMBL11572827 0.78 DAO (0.51) KMT2AKDM4EMAPTHPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed
US-20190334099-A1 TRANSITION METAL COMPLEX AND APPLICATION THEREOF, MIXTURE AND ORGANIC ELECTRONIC DEVICE GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG KMT2A 1976/4885ADRA2A 4635/4885KDM4E 1181/4885
US-20190334099-A1 TRANSITION METAL COMPLEX AND APPLICATION THEREOF, MIXTURE AND ORGANIC ELECTRONIC DEVICE AP1M1, MT-CO1, OSTC KMT2A 2675/4885ADRA2A 4562/4885KDM4E 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.